CT Imaging for Guiding PA-TACE for HCC

Zhujiang Hospital1,770 enrolled

Overview

Postoperative adjuvant transarterial chemoembolization (PA-TACE) may improve survival outcomes in a subset of patients with resected hepatocellular carcinoma (HCC), reliable biomarkers for the criterion for the selection of candidates are lacking. The present study aimed to evaluate whether CT imaging can provide more value for predicting benefit from PA-TACE.

Study Type

OBSERVATIONAL

Enrollment

1,770

Conditions

Carcinoma, Hepatocellular

Interventions

postoperative adjuvant transarterial chemoembolizationPROCEDURE

HCC patients received hepatectomy and PA-TACE.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * CT scans acquired no more than one month before surgery * Confirmation of HCC diagnosis by pathological examination * Curative surgical resection Exclusion Criteria: * Prior antitumor treatment * Macrovascular thrombosis or metastasis * Perioperative mortality * Unqualified image artifacts * Tumor rupture * MVI status not reported

Locations (1)

ZhuJiang Hospital of Southern Medical University

Guangzhou, Guangdong, China

Outcomes

Primary Outcomes

Overall survival

Overall survival was calculated from the date of hepatectomy to the last follow-up or until death, whichever came first.

Time frame: the date of hepatectomy to the last follow-up or until death, whichever came first, assessed up to 120 months.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.